is a Knowledge Graph.
Open Targets is a collaborative effort to systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases.
health, biomedical
Unknown
Unknown
Github: opentargets
Email: contact@opentargets.org
| ID | Name | URL | Category | Format | Description |
|---|---|---|---|---|---|
| opentargets.platform | Open Targets Platform | platform.opentargets.org | GraphicalInterface | http | The Open Targets Platform integrates ... |
| opentargets.api.graphql | Open Targets Platform GraphQL API | graphql | ProgrammingInterface | ❔ | GraphQL API for accessing Open Target... |
| opentargets.api.rest | Open Targets Platform REST API | rest | ProgrammingInterface | ❔ | REST API for accessing Open Targets P... |
| ID | Name | URL | Category | Format | Description |
|---|---|---|---|---|---|
| ubkg.neo4j | UBKG Neo4j Docker Distribution | ubkg-downloads.xconsortia.org | GraphProduct | ❔ | Turnkey neo4j distributions that depl... |
| ubkg.csv | UBKG Ontology CSV Files | ubkg-downloads.xconsortia.org | GraphProduct | csv | Ontology CSV files that can be import... |
| bioteque.embeddings | Bioteque Embeddings | embeddings | Product | ❔ | Network embeddings of the Bioteque gr... |
| epigraphdb.graph | EpiGraphDB Graph Database | graph-database | GraphProduct | neo4j | Integrated graph knowledge base combi... |
Open Targets is a pre-competitive partnership that systematically identifies and prioritizes drug targets to improve the success rate for developing safe and effective medicines. The consortium brings together expertise from leading pharmaceutical companies and academic research institutions to generate and integrate public data for better target selection in drug discovery.
Open Targets was established as a public-private partnership to use human genetics and genomics data for systematic drug target identification and prioritization. The consortium is built on three core principles:
The consortium is formed by partner institutions including the European Bioinformatics Institute (EMBL-EBI), Genentech, GSK, MSD, Pfizer, Sanofi, and the Wellcome Sanger Institute.
The Open Targets Platform is the flagship product that integrates public data relevant to the associations between targets and diseases. It provides evidence-based validation for therapeutic targets by bringing together information from genetics, genomics, transcriptomics, drugs, animal models, and scientific literature. The Platform helps researchers:
The Open Targets Genetics portal provides access to genetics data from genome-wide association studies (GWAS) and connects these to potential causal genes using various functional genomics data types. It helps researchers:
Open Targets’ core bioinformatics work focuses on bringing together various data types relevant to human disease biology and target identification. The data ecosystem includes:
All data is made available through user-friendly web interfaces and APIs (GraphQL and REST) that allow programmatic access for integration into computational workflows.
Open Targets’ research program focuses on three main therapeutic areas:
The consortium applies whole genome approaches and high-throughput methods to these disease areas, leveraging the expertise of all partners in emerging and established technologies.
Open Targets is committed to open science principles. Its software, data, and methods are publicly available, with code repositories accessible on GitHub. This open approach facilitates collaboration and encourages the broader scientific community to build upon and extend Open Targets’ work.
By providing systematic evidence for target-disease associations, Open Targets helps to address one of the key challenges in drug development: selecting the right targets. The platform reduces the risk of failure in later clinical development by enabling data-driven decisions early in the drug discovery process.
Through its integrated data resources and research programs, Open Targets is transforming how targets are selected for drug discovery, leading to more effective treatments for patients with both common and rare diseases.
Created: May 29, 2025 | Last modified: January 06, 2026